simethicone and Colonic-Diseases--Functional

Topics: Aerophagy; Antifoaming Agents; Colic; Colonic Diseases, Functional; Combined Modality Therapy; Constipation; Diet; Dietary Fiber; Diffusion; Eructation; Fermentation; Flatulence; Gases; Gastrointestinal Motility; Intestines; Parasympatholytics; Simethicone

In an open safety-in-use study, the subjective effectiveness and taste acceptability of a new high-potency antacid product were compared to previous treatment in 109 patients presenting with upper gastro-intestinal disorders of functional origin. Severity of the dominant symptoms prior to treatment was compared with that of symptoms present during treatment. Sixty-seven per cent to 73% of upper gastro-intestinal tract symptoms were completely relieved. Eighty-three per cent versus 48% of patients seen in a private practice setting, as compared with the speciality practice, reported good to excellent results, with 92% versus 56% describing good to excellent taste acceptability. When compared with previous antacid therapy, 70% of the patients preferred the new high-potency formulation to the regular-strength products, for both effectiveness and taste. The incidence of product-related side-effects was low, with only 6.7% experiencing the diarrhoea or loose stools commonly associated with conventional products containing magnesium hydroxide.

Topics: Adolescent; Adult; Aged; Aluminum Hydroxide; Antacids; Colonic Diseases, Functional; Constipation; Diarrhea; Drug Combinations; Drug Evaluation; Dyspepsia; Esophagitis, Peptic; Female; Gastritis; Humans; Magnesium; Magnesium Hydroxide; Male; Middle Aged; Silicones; Simethicone

Topics: Adrenergic beta-Antagonists; Colonic Diseases, Functional; Dietary Fiber; Dyspepsia; Humans; Parasympatholytics; Psychotropic Drugs; Simethicone